An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Latest Information Update: 27 May 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Proteinuria; Renal failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIONA OLE
- Sponsors Bayer
Most Recent Events
- 17 Dec 2024 Planned End Date changed from 31 Dec 2028 to 27 Feb 2029.
- 17 Dec 2024 Planned primary completion date changed from 31 Dec 2028 to 28 Jan 2029.
- 09 Dec 2024 Planned End Date changed from 10 Sep 2028 to 31 Dec 2028.